Evotec Announces TargetAD Collaboration With Johnson & Johnson Innovation to Identify and Develop Novel Alzheimer's Disease

Evotec Announces TargetAD Collaboration With Johnson & Johnson Innovation to
Identify and Develop Novel Alzheimer's Disease Therapies

  oCollaborative effort will explore genes dysregulated in Alzheimer's
    disease patients to identify new targets for drug discovery and

HAMBURG, Germany, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN:DE0005664809) today announced a collaboration with the Johnson
& Johnson Innovation Center in California to identify new targets for
Alzheimer's disease drug discovery and development. Under the terms of the
agreement, Janssen Pharmaceuticals, Inc. ("Janssen"), a member of the Johnson
& Johnson family of companies, and Evotec will work together to discover and
develop novel treatments for Alzheimer's disease.

Termed TargetAD (Alzheimer's disease),the collaboration will seek to identify
new drug targets for discovery of novel treatment approaches to Alzheimer's
disease ("AD"). Janssen will fund target discovery research via a combination
of defined research payments and progress-related milestones over the next
three years.

Janssen will have the opportunity to internalise selected targets and
therapeutic candidates from the TargetAD database and progress them into
pre-clinical and clinical development. Janssen will reimburse up to $
10million in FTE-based research costs and make pre-clinical, clinical,
regulatory and commercial payments up to a maximum of between approximately
$125million to $145million per programme upon achieving agreed-upon
milestones. In addition, Evotec will receive royalties on future sales of any
products that may result from the alliance.

Evotec's proprietary TargetAD database provides a unique source of potentially
novel Alzheimer's disease drug targets derived from the analysis of
dysregulated genes in high-quality and well-characterised human brain tissues
representing all stages of disease progression as well as control tissues from
non-demented subjects. Identifying new targets for drug development based on
disease pathology may have the potential to impact the disease at its earliest
stages, resulting in greater therapeutic benefit to patients.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, added: "The TargetAD
alliance provides a systematic and comprehensive approach to the discovery of
novel drug AD targets which leverages Evotec's strength in neuroscience
discovery with Janssen's pre-clinical and clinical drug development
capabilities for the discovery of novel treatments for Alzheimer's disease."


TheTargetADdatabase is a customised system providing
uniqueinformationonthe link betweenmolecularand cellularchanges in brain
tissuewithAD progression.This database was set upin amulti-year research
programme,applying histological, cellular and in vivo target
validationprocedures.The databaseprovides a strong foundation for
systematic collaborative target validation and compound discovery programmes.


Alzheimer's disease (AD) is an irreversible, progressive brain disease. It
slowly destroys brain cells and nerves and thus disrupts the transmitters
which carry messages in the brain, particularly those responsible for storing
memories. The disease is named after the German psychiatrist and
neuropathologist Alois Alzheimer who described the first case of presenile
dementia. The cause and progression of AD are still not completely understood.
Conducted research indicates that the disease is associated with plaques and
tangles in the brain. In the course of AD, the brain shrinks as gaps develop
in the temporal lobe and hippocampus, which are responsible for storing and
retrieving new information. Like other chronic conditions, scientists believe
that AD doesn't have one predominant cause but is rather a complex result of
various factors. At the moment, there is no cure available for AD and most
other causes for dementia. Current treatments only tackle the symptoms of the
disease. According to the World Alzheimer Report 2012 published by Alzheimer's
Disease International, there were 36 million people diagnosed with dementia in
2010 worldwide. Approximately 7.7 million new cases of dementia are diagnosed
each year. Concerning the dementia market volume, $604bn were spent on the
treatment of dementia in 2010. All in all, these costs equal about 1% of the
world's GDP (average of GDP from countries worldwide).


Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
Press spacebar to pause and continue. Press esc to stop.